Alvotech
HealthcareNASDAQ:ALVO · NASDAQ Global Market
-$0.05 today
Vol 0.53M · Avg 0.57M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$559.4M of revenue converted into -$80.7M of net income for the selected period. Gross margin is 61.6% and net margin is -12.6%, showing how much revenue survives after costs and taxes. EPS is $-0.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $586.3M +19.7% | $489.7M +435.6% | $91.4M +10.1% | $83.0M +125.8% | $36.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $235.6M +27.1% | $185.3M +15.2% | $160.9M +151.0% | $64.1M | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $350.8M +15.2% | $304.4M +538.4% | -$69.4M -466.7% | $18.9M -48.5% | $36.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 59.8% -2.3pp | 62.2% +138.1pp | -75.9% -98.7pp | 22.8% -77.2pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $184.2M +7.5% | $171.3M -18.7% | $210.8M +16.7% | $180.6M -5.4% | $191.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $90.9M +48.0% | $61.5M -15.9% | $73.0M -60.9% | $186.7M +122.0% | $84.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $272.6M +16.1% | $234.7M -17.8% | $285.4M -21.9% | $365.4M +34.2% | $272.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $37.9M +20.9% | $31.3M +29.3% | $24.2M +18.6% | $20.4M +12.2% | $18.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $323.4M +1102.0% | -$32.3M +93.5% | -$493.7M -12.2% | -$439.8M -2339.1% | -$18.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 55.2% +61.7pp | -6.6% +533.3pp | -539.9% -10.2pp | -529.7% -480.7pp | -49.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $78.2M +12.3% | $69.6M +119.6% | -$354.9M -2.4% | -$346.4M -47.1% | -$235.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 13.3% -0.9pp | 14.2% +402.3pp | -388.1% +29.1pp | -417.3% +223.1pp | -640.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $198.5M +4199.2% | $4.6M -4.3% | $4.8M +428.8% | $912.0K +4700.0% | $19.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $149.2M -5.3% | $157.6M +16.9% | $134.8M +47.4% | $91.4M -19.1% | $113.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $58.1M +120.2% | -$287.2M +3.0% | -$296.2M -44.3% | -$205.2M -337.9% | $86.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $136.3M +162.7% | -$217.6M +66.6% | -$651.0M -18.0% | -$551.6M -269.7% | -$149.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 23.3% +67.7pp | -44.4% +667.6pp | -712.0% -47.6pp | -664.4% -258.7pp | -405.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $108.4M +658.2% | $14.3M +114.4% | -$99.3M -160.9% | -$38.1M +20.2% | -$47.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | $27.9M +112.0% | -$231.9M +58.0% | -$551.7M -7.4% | -$513.6M -406.0% | -$101.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 4.8% +52.1pp | -47.3% +556.1pp | -603.4% +15.1pp | -618.6% -342.5pp | -276.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +111.5% | -$1 +64.2% | -$2 +6.5% | -$3 +20.0% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +111.5% | -$1 +64.2% | -$2 +6.5% | -$3 +20.0% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $279.2M +4.2% | $267.9M +17.9% | $227.3M +14.9% | $197.7M +532.7% | $31.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $279.2M +4.2% | $267.9M +17.9% | $227.3M +14.9% | $197.7M +532.7% | $31.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ALVO generate?
Alvotech (ALVO) reported $586.32M of revenue in fiscal 2025.
Is ALVO profitable?
Alvotech (ALVO) reported $27.92M of net income, with a net margin of 4.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.